Second Securities Fraud Class Action Filed Against GRAIL Over NHS-Galleri Trial
GRAL has more than doubled off its 52-week low of $29.95.
Summary
Bleichmar Fonti & Auld LLP filed a securities fraud class action against GRAIL, alleging the company misled investors about the NHS-Galleri trial's ability to meet its primary endpoint. This follows a similar lawsuit announced by Hagens Berman on June 29, indicating mounting legal pressure. The complaint cites the 50.55% stock drop on February 20, 2026, after GRAIL disclosed the trial failed to show a statistically significant reduction in late-stage cancers. Investors have until August 4, 2026, to seek lead plaintiff status. The case adds to the company's legal risks, though the underlying trial results were already known.
At the time of this announcement, GRAL was trading at $71.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $29.95 to $118.84. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: PR Newswire.